DynaMed Plus® Levels of Evidence
Table of contents:

Levels of Evidence

*DynaMed* provides easy-to-interpret Level of Evidence labels so users can quickly find and determine the quality of the best available evidence. Evidence may be labeled in one of three levels:

Level 1.................................................................................................................................. 3
Level 2.................................................................................................................................. 5
Level 3.................................................................................................................................. 5
Distinguishing Clinical Outcomes from Surrogate Outcomes........ 6
Level 1

**Level 1 (likely reliable) Evidence** - representing research results addressing clinical outcomes and meeting an extensive set of quality criteria which minimizes bias.

**Levels of evidence for conclusions derived from individual studies:**

- *DynaMed* criteria for Level 1 (likely reliable) evidence for interventional conclusion (conclusions that an intervention does or does not change an outcome):
  1. Full-text report available in English (or language well understood by participating editor)
  2. Clinical outcome (also called patient-oriented outcomes)
  3. Population, intervention, comparison and outcome in the study is representative of expected clinical practice
  4. Random allocation method (i.e., not assigned by date of birth, day of presentation, “every other”)
  5. Blinding of all persons (patient, treating clinician, outcome assessor) if possible
  6. Follow up (endpoint assessment) of at least 80% of study entrants AND adequate such that losses to follow-up could not materially change the results
  7. Accounting for dropouts (even if not included in analysis)
  8. Adequate precision of effect estimate based on:
     - Confidence intervals do not include both presence of no effect (relative risk 0.9-1.1) and presence of substantial relative effect (such as relative risk <0.75 or >1.25)
     - Adequate power (based on sample size and observed control event rate) to detect clinically important differences
  9. Consistency of findings across measures of similar outcomes
  10. In cases of randomized parallel-group trials:
      - Allocation concealment
      - Intention-to-treat analysis comparing groups according to randomization
  11. In cases of randomized crossover trials
      - Trial conducted in patients with condition not expected to change spontaneously during course of trial
      - Random allocation method for order of assignment
      - Washout period between interventions is long enough to avoid carryover effects between interventions
      - Adequate duration of intervention and assessment period to represent outcome being measured
      - Analysis of paired data
      - Analysis not suggesting period effects (i.e., effect resulting for order of intervention) or period effects if present not materially changing results
  12. In cases of early trial termination:
      - Stopping decision made by independent monitoring board without competing interests
      - Interim analysis preplanned
      - Statistical stopping rule accounts for multiple assessments (lower p value threshold) for early termination benefit
      - Clinically significant differences with absolute benefit/harm warranting early termination
      - For classification of level of evidence for a specific outcome (which may be different than outcome used for stopping decision), outcome has sufficient statistical results such that trial continuation would be unlikely to change these results
13. No other factors contributing to substantial bias, such as:
   • Differences in management between groups other than the intervention being studied
   • Differential loss to follow-up
   • Posthoc analysis
   • Subgroup analysis
   • Baseline differences between groups
   • Unclear how missing data are accounted for if possible

   *DynaMed* criteria for Level 1 (likely reliable) evidence for a diagnostic conclusion:
   1. Full-text report available in English (or language well understood by participating editor)
   2. Patient sample represents patients for whom testing would be appropriate (i.e., diagnostic uncertainty)
   3. Reliable reference standard
   4. Test under investigation is representative of how test would be conducted in clinical practice
   5. Reference standard and test under investigation each applied to all study subjects (with or without diagnosis)
   6. Test under investigation conducted blinded to and independent of reference standard results
   7. Reference standard conducted blinded to and independent of study test results
   8. Adequate follow up and accounting for subjects
   9. Confidence intervals do not include both presence and absence of clinically meaningful differences
   10. Test studied in independent validation cohort (i.e., a cohort that is independent from the derivation of the test or specific cutoff value being investigated)
   11. No other factors contributing substantial bias

   *DynaMed* criteria for Level 1 (likely reliable) evidence for a prognostic conclusion:
   1. Full-text report available in English (or language well understood by participating editor)
   2. Inception cohort study
   3. Prospective follow-up
   4. Representative sample at a similar course in the disease
   5. Follow up sufficiently long and complete
   6. Systematic (unbiased) evaluation of outcomes
   7. Adjustments for important, confounding factors
   8. Confidence intervals do not include both presence and absence of clinically meaningful differences
   9. Additional criteria for prediction rules:
      • Validation in relevant population
      • Validation in sample independent from derivation cohort
   10. No other factors contributing to substantial bias

Levels of evidence for conclusions regarding a body of evidence:

   *DynaMed* criteria for Level 1 (likely reliable) evidence for conclusions from a systematic review:
   1. Full-text report available in English (or language well understood by participating editor)
   2. Clinical outcome (also called patient-oriented outcomes)
   3. Systematic search
   4. Explicit inclusion criteria that do not appear to inappropriately exclude important evidence
   5. Systematic selection of included studies
6. Key factors analyzed from included studies are representative of expected clinical practice:
   • For interventional conclusions key factors are population, intervention, comparison and outcome
   • For diagnostic conclusions key factors are population, test under investigation and reference standard
   • For prognostic conclusions key factors are population and outcome
7. Evaluation of study quality sufficient to determine if individual studies meet Level 1 evidence criteria
8. Consistency of findings across studies (whether or not meta-analysis performed)
9. Consistency of findings across measures of similar outcomes
10. Additional criteria if meta-analysis:
    • Studies are clinically appropriate for pooled analysis (reasonably similar populations, interventions, methodology and outcomes)
    • Meta-analysis not limited by statistically significant heterogeneity
11. Conclusion based on 1 or more primary studies meeting Level 1 evidence criteria
12. Adequate precision of effect estimate based on:
    • Confidence intervals do not include both presence of no effect (relative risk 0.9-1.1) and presence of substantial relative effect (such as relative risk <0.75 or >1.25)
    • Adequate power (based on sample size and observed control event rate) to detect clinically important differences
13. No strong suspicion of publication bias
14. No other factors contributing substantial bias, such as subgroup analysis or indirect comparisons

• DynaMed Plus criteria for Level 1 (likely reliable) evidence for conclusions from a synthesis of systematic literature surveillance:
  1. Conclusions are consistent with 1 or more primary studies meeting Level 1 evidence criteria
  2. Key factors analyzed from included studies are representative of expected clinical practice:
     • For interventional conclusions key factors are population, intervention, comparison, and outcome
     • For diagnostic conclusions key factors are population, test under investigation and reference standard
     • For prognostic conclusions key factors are population and outcome
  3. MEDLINE search conducted to exclude conflicting evidence (to supplement systematic literature surveillance)
  4. Consistency of findings across studies
  5. Consistency of findings across measures of similar outcomes
  6. No strong suspicion of publication bias

Level 2

Level 2 (mid-level) Evidence - representing research results addressing clinical outcomes, and using some method of scientific investigation, but not meeting the quality criteria to achieve Level 1 evidence labeling.

Level 3

Level 3 (lacking direct) Evidence - representing reports that are not based on scientific analysis of clinical outcomes. Examples include case series, case reports, expert opinion, and conclusions extrapolated indirectly from scientific studies.
**Distinguishing Clinical Outcomes from Surrogate Outcomes**

Clinical outcomes may also be called patient-oriented outcomes or patient-important outcomes.

An outcome (in evidence regarding the effect of interventions) is considered a clinical outcome (and not a surrogate outcome) if any of the following criteria are met:

1. The outcome is a direct measure of things that directly impact a patient’s well-being, such as symptoms, functional ability or quality of life
2. The outcome is directly and immediately attributed to symptoms (i.e., detection of diagnosis as an outcome where diagnosis is based on symptomatic presentation)
3. The outcome represents an established risk of harm (symptoms, disability or reduced quality of life) to other people

In conclusions regarding the effects of interventions, conclusions about effects on surrogate outcomes will be rated level 3 [lacking direct] evidence, except that ratings of level 2 [mid-level] evidence can be applied if both of the following criteria are met:

1. The surrogate measure lies in the causal pathway to an effect on a clinical outcome
2. A change in the surrogate measure (for a defined magnitude and duration) is validated to predict the likelihood of a clinical outcome